Thursday, November 18, 2010

Significance in food production


biotechnology- Significance in food production


The significance of the application of modern biotechnology in the area of food production and its resultant impact in terms of human health and development can not be undermined. As the world is faced with ever increasing population and more and more food shortage and regional imbalances, new technologies and techniques are being developed to enhance production and increase the shelf life of perishable items. It is in this direction that new research initiatives in the field of green biotechnology are being made to enhance productivity and nutrition value of food items.

Foods produced through modern biotechnology can be categorized as follows:

1. Foods consisting of or containing living/viable organisms, e.g. maize.

2. Foods derived from or containing ingredients derived from Genetically Modified Organisms (GMOs), e.g. flour, food protein products, or oil from GM soybeans, wheat etc.

3. Foods containing single ingredients or additives produced by GM microorganisms (GMMs), e.g. colours, vitamins and essential amino acids.

4. Foods containing ingredients processed by enzymes produced through GMMs, e.g. high-fructose corn syrup produced from starch, using the enzyme glucose isomerase (product of a GMM).

The first genetically modified food item -GM food (delayed-ripening tomato) was introduced on the US market in the mid-1990s. Since then, GM strains of maize, soybean, rape and cotton have been adopted by a number of countries and marketed internationally. In addition, GM varieties of papaya, potato, rice, squash and sugar beet have been trialed or released. It is estimated that GM crops cover almost 4% of total global arable land.

The development of GM organisms has revolutionized the scenario of world food production. It has also offered the potential for increased agricultural productivity or improved nutritional value that can contribute directly to enhancing human health and development. From a health perspective, there may also be indirect benefits, such as reduced agricultural chemical usage and enhanced farm income, and improved crop sustainability and food security, particularly in developing countries.

While the introduction of GM crops has undoubtedly changed the agricultural scenario and led to significant impact on human development, it has also raised various social, cultural and ethical issues and reluctance on the part of various countries and governments to accept the GM food even in times of grave needs such as famine and drought. While some countries have established premarket regulatory standards for risk assessment of each and every food item before being launched in the market for application, there may be a case of a consistent and uniform international regulatory structure so as to ensure that such food items conform to a set of standards which are fair and equitable. This will also help quell a number of misgivings and doubts in the minds of countries yet to benefit from these food items.
Read more »

Wednesday, November 10, 2010

biotech jobs

Rajiv Gandhi Centre for Biotechnology (RGCB) is an autonomous institution fully funded by the Department of Biotechnology, Government of India (www.rgcb.res.in). RGCB has a major research program with the International Agency for Research Against Cancer (World Health Organization) on Human Papillomaviruses (HPV) including a state of the art efficacy-testing center for HPV vaccines.

RGCB invites applications for the position of Research Scientist or Visiting Scientist or Senior Research Associate or Post Doctoral Fellow from persons with a PhD in Life Sciences or MD in Virology, Pathology or Microbiology with previous experience in HPV research, diagnosis, detection methods, serology, cytology, pathobiology, etc. The job involves management of the HPV research facility, developing new HPV research programs and providing support to vaccine trials (antibody titers, genotyping, immune assays, etc). The position offer and monthly emoluments will depend on experience and performance record (number and quality of publications, track record, etc). The position of Research Scientist will be on the terms and conditions laid down by the Ministry of Science & Technology (Government of India). Persons in permanent employment can also be considered on deputation as per Government of India regulations and conditions. The position is temporary and will be for an initial period of one year, extendable to three years based on performance. Further extension beyond 3 years will depend on continuation of the grant from WHO and other institutional requirements. Applications with Curriculum Vitae, List of Publications & other achievements and three letters of reference may be submitted to the Director, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014

Read more »

Monday, November 8, 2010

biotechnology journal




click here ...

In addition to maintaining the GenBank® nucleic acid sequence database, the National Center for Biotechnology Information (NCBI) provides analysis and retrieval resources for the data in GenBank and other biological data made available through NCBI's Web site. NCBI resources include Entrez, the Entrez Programming Utilities, My NCBI, PubMed, PubMed Central, Entrez Gene, the NCBI Taxonomy Browser, BLAST, BLAST Link(BLink), Electronic PCR, OrfFinder, Spidey, Splign, RefSeq, UniGene, HomoloGene, ProtEST, dbMHC, dbSNP, Cancer Chromosomes, Entrez Genome, Genome Project and related tools, the Trace and Assembly Archives, the Map Viewer, Model Maker, Evidence Viewer, Clusters of Orthologous Groups (COGs), Viral Genotyping Tools, Influenza Viral Resources, HIV-1/Human Protein Interaction Database, Gene Expression Omnibus (GEO), Entrez Probe, GENSAT, Online Mendelian Inheritance in Man (OMIM), Online Mendelian Inheritance in Animals (OMIA), the Molecular Modeling Database (MMDB), the Conserved Domain Database (CDD), the Conserved Domain Architecture Retrieval Tool (CDART) and the PubChem suite of small molecule databases. Augmenting many of the Web applications are custom implementations of the BLAST program optimized to search specialized data sets. These resources can be accessed through the NCBI home page at www.ncbi.nlm.nih.gov.
Read more »

Friday, September 3, 2010

biotech robotics


Biotechnology material handling applications are among some of the fastest growing areas of robotics. Drug discovery and vaccines research have moved material handling robotics from the factory floor to academic laboratories and to research and development departments of biotechnology firms.

Biotech vs. Non-Biotech
Biotech is not just another industrial material handling applications. While there are some similarities between biotech material handling and non-biotech work cells, some major differences exist.

‘‘The major difference of biotech material handling applications is the need for flexibility and multi-tasking,’‘ said Michael Perreault. ‘‘Biotech work cells have the ability to run several processes simultaneously.’‘ Perreault is vice president of Midmac Systems, Inc., an engineering services and a robotic system integrator located in St. Paul, Minnesota. Perreault added that biotech work cells tend to have smaller batch runs than non-biotech material handling applications.

Trevor Jones of Thermo CRS agrees with Perreault for the need of more flexibility in biotech over non-biotech work cells. Jones is director of OEM business development at Thermo CRS, a system integrator and robot manufacturer in Burlington, Ontario.

‘‘The major difference between biotech and non-biotech material handling work cells is the use of software. Biotech applications require more flexibility than traditional material handling operations,’‘ Jones said. ‘‘In an industrial work cell, designers are much more concerned with achieving a fixed optimum output so they install dedicated end-effecters for achieving a single purpose at that time in a manufacturing plant.’‘

In biotech systems, software manages the throughput of each micro-titer plate to best utilize the available hardware. Biotech hardware has to deal with frequently changing assays. It is common to run multiple assays through a system simultaneously.
Read more »

Saturday, April 24, 2010

Bt Brinjal


The debate over the petridish baingan is hotting up. Environment minister Jairam Ramesh's sudden recourse to public consultations, after Bt Brinjal was cleared as India's first genetically modified food crop, has exposed serious regulatory lapses. TOI-Crest looks at the challenge posed by this humble vegetable ...

The cutting-edge technology of Bt brinjal has had an unintended consequence. The public outrage that followed the regulatory clearance of the first ever GM food crop has forced environment minister Jairam Ramesh to adopt an innovation in public administration. No minister has ever before crisscrossed the country to hold a series of public consultations, that too on a policy matter already approved by a statutory regulator. Ramesh has announced that he would present his findings to the prime minister shortly following the last of the seven consultation meetings due in Bangalore on February 6.

Ramesh came up with the device of public consultations on October 15, 2009, just a day after the regulator in his ministry, the Genetic Engineering Approval Committee (GEAC), had given its go-ahead to the commercial cultivation of Bt brinjal. The series of consultation meetings chaired by him, starting in Kolkata on January 13, have turned out to be as dramatic, given the manner in which pro and anti-GM lobbies sought to demonstrate not only the strength of their arguments but also their lung power.

Not surprisingly, the sharp divide over Bt brinjal has had political ramifications. Ramesh suffered the mortification of seeing two of his colleagues in the Central government, agriculture minister Sharad Pawar and science and technology minister Prithviraj Chavan, publicly criticising the ad hoc measure adopted by him despite the GEAC's clearance.

Ramesh responded by asserting that he was not bound by the GEAC's recommendations and that he was entitled to take public concerns on board.

The issue acquired greater traction as eight state governments came out against Bt brinjal, in varying forms and degrees. And those states cut across regional and political lines: Kerala, Karnataka, Andhra Pradesh, Madhya Pradesh, Chhattisgarh, Orissa, West Bengal and Bihar. While some asked for a moratorium pending further testing of the bio-safety of Bt brinjal, others rejected the very idea of letting toxic genes be inserted into food crops.

Thus, at a time when he has been grappling with the climate change debate at the global level, Ramesh has been embroiled locally in the controversy over GM crops, seven years after Bt cotton had been introduced in India by the American MNC Monsanto.

Bt brinjal was the second GM crop to be cleared by the GEAC, this one at the instance of Monsanto's Indian associate, Maharashtra Hybrid Seeds Company (Mahyco). And this is just the beginning of what could be a biotech revolution, for better or for worse, as many more crops, including cash crops, vegetables, fruits, cereals and pulses, are in the regulatory pipeline.

GM technology, in which a gene is transferred from a different species to imbibe a desirable trait, is touted as a long-term solution to the problems of pests, hunger, drought and even climate change. Though the technology warrants serious consideration, the uproar over Bt brinjal has served to highlight a trust deficit in the regulatory system created under statutory rules framed in 1989. The GEAC, headed by an additional secretary in the environment ministry, invariably a nonspecialist IAS officer, has failed to inspire confidence in its ability to regulate a high-stakes but inherently risky technology that involves tampering with nature.

If the minister was forced to announce public consultations within a day of the GEAC's muchawaited decision on Bt brinjal, it is thanks to a series of regulatory lapses that have surfaced since at least 2006, when the Supreme Court restrained it from approving any fresh field trials. Much as it was a blow to the credibility of the regulatory system, a bench headed by the then Chief Justice of India, Y K Sabharwal, felt compelled to pass such an interim injunction as the GEAC had evidently abdicated its duty to independently examine the environmental and biosafety aspects of the proposed GM crops.

In the course of a PIL filed by activist Aruna Rodrigues seeking a moratorium on GM crops, the apex court was appalled to discover that the GEAC was rubberstamping recommendations made by the Review Committee on Genetic Manipulation (RCGM), which is part of the Department of Biotechnology, an avowed promoter of GM crops. The evidence of the GEAC's cavalier attitude lay in its minutes, which showed that in a single meeting it had cleared 91 field trials across 10 food crops.

But eight months later, thanks to the vagaries of the judicial process, a bench headed by Justice Sabharwal's successor, Justice K G Balakrishnan, vacated the stay on the GEAC. This proved propitious to Mahyco's pending application for permission to initiate large-scale field trials of Bt brinjal. The GEAC promptly granted permission. That is how, after carrying out large-scale field trials for two years, Mahyco sought to clear the final regulatory hurdle in 2009 for commercial cultivation of Bt brinjal.

The GEAC's final clearance to Bt brinjal on October 14, 2009, provoked fresh questions about its capacity and will to regulate. For, the GEAC gave little indication of mending its ways after the Supreme Court had restored its powers in May 2007.

Consider the manner in which it had subverted the same Supreme Court order on the issue of transparency. Justice Balakrishnan's bench had directed that Mahyco's bio-safety dossier on Bt brinjal be posted on the GEAC's website. But all that the GEAC put out was Mahyco's analysis and conclusions. It withheld all the raw data that would have helped experts outside the GEAC to make an independent assessment of the bio-safety claims.

It took a contempt petition before the Supreme Court for the GEAC to disclose the raw data at last in August 2008, covering, among other things, a 90-day feeding study on rats. Since international experts gave adverse feedback on the raw data, the GEAC set up an expert committee under its co-chairman , Arjula Reddy, in January 2009, in a bid to allay public apprehensions.

The expert committee concluded that Bt brinjal was "safe for environmental release in India" and that its benefits "far outweigh the perceived and projected risks" . The committee's report came on October 8 and the GEAC gave its clearance six days later. And that was despite the dissent recorded by the Supreme Court's nominee to the GEAC, P M Bhargava, saying, "he is not against GM crops, but cannot support the proposal as the safety assessment in his view is not complete" .

Bhargava's view on the incompleteness of the safety assessment was vindicated by the GEAC's disclosure of another installment of raw data on the bio-safety of Bt brinjal on November 17, more than a month after it had already cleared the crop.

Since Jairam Ramesh had by then distanced himself from it in the wake of public outrage, the GEAC made a belated disclosure of the data relating to the crucial aspect of gene flows (concerning the contamination potential of Bt brinjal). It was forced by the allegations that some of the data relied upon by the expert committee had not been made public.

With friends like the GEAC, GM technology does not need enemies. Whether the benefits of Bt brinjal outweigh its risks or not, it has come under a cloud of suspicion because of the GEAC's overweening secrecy and lack of rigour. After his yatra of public consultations, Jairam Ramesh would have to be really brave to concur with the GEAC's view that Bt brinjal in its current state was safe for environmental release. In any event, he would do well to revamp the regulatory system.

Do risks exceed benefits?

THREAT TO BRINJAL DIVERSITY

Brinjal in its varied shapes and colours is said to have originated in India. Opponents of Bt brinjal, therefore, contend that genetic engineering should not be allowed in the "centre of origin" as it could lead to the loss of original varieties by transgenic cross-pollination .

Mahyco:

Its spokesperson, when contacted, brushed aside the 'centre of origin' argument saying, "The origin of cultivated brinjal is uncertain, with differing views put forward by scientists . South America and Indo-China are thought to be areas of origin. India is considered a centre of diversity."

IS THE TOXIN PUT IN BRINJAL SAFE FOR HUMAN CONSUMPTION?

Since Bt brinjal is fatal to a pest called fruit and shoot borer, some scientists question the premise that the Bt gene acts only in the alkaline environment found in the gut of insects. For, the human digestive system is acidic only in the stomach while the rest of it is alkaline. The study done by Mahyco on rats allegedly does not address possible human dangers such as cancer, infertility and kidney damage.

Counterview:

The Bt gene breaks down during digestion into common amino acids, which are part of the normal diet and are neither toxic nor allergic.

PRECAUTIONARY PRINCIPLE

Since Bt brinjal has been developed for the first time anywhere in the world, the precautionary principle requires that its clearance should have been withheld because of the uncertainty and irreversibility of its long-term implications for health and environment . Mahyco insists there is no cause for alarm over Bt Brinjal as Bt cotton, the GM crop introduced in India in 2002, "is already in our food chain" . For, about 11 lakh tons of Bt cotton oil is consumed annually by people, directly or through vanaspati. Mahyco claims, "As the Bt gene present in cotton is identical to that used in brinjal, there is a strong precedence for safety of the gene itself."

NO LABELING AND LIABILITY REGIME

Informed consumer choice requires that the introduction of Bt brinjal be put off till a mechanism of mandatory labeling is put in place. But then, how will GM food be labeled in a country where vegetables are not sold only in supermarkets? And how feasible is it to maintain the segregation from the field to the market? Worse, there is no law fixing liability in the event of contamination of non-Bt brinjal by the GM variety.
Read more »

Friday, March 26, 2010

Spying on a Cellular Director in the Cutting Room





Like a film director cutting out extraneous footage to create a blockbuster, the cellular machine called the spliceosome snips out unwanted stretches of genetic material and joins the remaining pieces to fashion a template for protein production.


But more than box office revenues are at stake: if the spliceosome makes a careless cut, disease likely results.

Using a new approach to studying the spliceosome, a team led by University of Michigan chemistry and biophysics professor Nils Walter, collaborating closely with a team led by internationally recognized splicing experts John Abelson and Christine Guthrie of the University of California, San Francisco, spied on the splicing process in single molecules.

The research is scheduled to be published online March 21 in Nature Structural and Molecular Biology.

Since its Nobel Prize-winning discovery in 1977, gene splicing has been studied in a number of organisms, including yeast and human cells, using both genetic and biochemical approaches. While these methods can yield snapshots, they can't monitor the ongoing process. The new study, which utilizes a technique called fluorescence resonance energy transfer (FRET) and a sophisticated microscope that watches single molecules in action, allows researchers to observe in real time the contortions involved in spliceosome assembly and operation.
Read more »

Wide Variety of Genetic Splicing in Embryonic Stem Cells Identified





Like tuning in to an elusive radio frequency in a busy city, human embryonic stem cells must sort through a seemingly endless number of options to settle on the specific genetic message, or station, that instructs them to become more-specialized cells in the body (Easy Listening, maybe, for skin cells, and Techno for neurons?). Now researchers at the Stanford University School of Medicine have shown that this tuning process is accomplished in part by restricting the number of messages, called transcripts, produced from each gene.


Most genes can yield a variety of transcripts through a process called splicing. Variations in the ways a gene is spliced can change the form and function of the final protein product. Nearly all our genes can be spliced in more than one way. This research is the first time, however, that splicing variety has been linked to the unprecedented developmental flexibility, or pluripotency, exhibited by embryonic stem cells.

"The embryonic stem cells are loaded with many splicing variants for each gene," said Michael Snyder, PhD, chair of Stanford's genetics department. "But as the cells differentiate and become more specialized, the number of types of transcripts decreases."

Snyder and his colleagues studied the changes in RNA transcript levels occurring as the embryonic stem cells were induced in a laboratory dish to differentiate into neural cells. (The creation of RNA transcripts is an intermediate step in the generation of proteins from DNA.) In the process they generated a unique "dictionary" of neural-specific splicing variants, or isoforms.
Read more »

'Doublesex' Gene Key to Determining Fruit Fly Gender





The brains of males and females, and how they use them, may be far more different then previously thought, at least in the fruit fly Drosophila melanogaster, according to research funded by the Wellcome Trust.

In a paper published in the journal Nature Neuroscience, researchers from the University of Glasgow and the University of Oxford, have shown that the gene known as 'doublesex' (dsx), which determines the shape and structure of the male and female body in the fruit fly, also sculpts the architecture of their brain and nervous system, resulting in sex-specific behaviours.

The courtship behaviour of the fruit fly has long been used to study the relationship between genes and behaviour: it is innate, manifesting in a series of stereotypical behaviours largely performed by the male. The male chases an initially unreceptive female, and 'woos' her through tapping and licking and using wing vibration to generate a 'courtship' song. If successful, the female will slow and present a receptive posture, which allows copulation to occur.

For some time now, the gene 'fruitless' (fru), which is specific to the adult male fruit fly, was thought to be the key to male behaviour and the development of male specific neural circuitry of flies.
Read more »

Monday, March 8, 2010

Bio Weapons

Rapid developments in biotechnology, genetics and genomics are undoubtedly creating a variety of environmental, ethical, political and social challenges for advanced societies. But they also have severe implications for international peace and security because they open up tremendous avenues for the creation of new biological weapons.

The genetically engineered 'superbug'—highly lethal and resistant to environmental influence or any medical treatment—is only a small part of this story. Much more alarming, from an arms-control perspective, are the possibilities of developing completely novel weapons on the basis of knowledge provided by biomedical research—developments that are already taking place.

Such weapons, designed for new types of conflicts and warfare scenarios, secret operations or sabotage activities, are not mere science fiction, but are increasingly becoming a reality that we have to face. Here, we provide a systematic overview of the possible impact of biotechnology on the development of biological weapons.


The history of biological warfare is nearly as old as the history of warfare itself. In ancient times, warring parties poisoned wells or used arrowheads with natural toxins. Mongol invaders catapulted plague victims into besieged cities, probably causing the first great plague epidemic in Europe, and British settlers distributed smallpox-infected blankets to native Americans.


Indeed, the insights into the nature of infectious diseases gained by Louis Pasteur and Robert Koch in the nineteenth century did not actually represent a great breakthrough in the use of infectious organisms as biological weapons. Similarly, the development of a bioweapon does not necessarily require genetic engineering—smallpox, plague and anthrax are deadly enough in their natural states. But the revolution in biotechnology, namely the new tools for analysing and specifically changing an organism's genetic material, has led to an increased risk of biowarfare due to several factors.

First, the expansion of modern biotechnology in medical and pharmaceutical research and production has led to a worldwide availability of knowledge and facilities. Many countries and regions, where 30 years ago biotechnology merely meant brewing beer and baking bread, have established high-tech facilities for vaccine or single-cell-protein production that could be subverted for the production of biological weapons. Today, nearly all countries have the technological potential to produce large amounts of pathogenic microorganisms safely.


Second, classical biowarfare agents can be made much more efficiently than their natural counterparts, with even the simplest genetic techniques.

Third, with modern biotechnology it becomes possible to create completely new biological weapons. And for technical and/or moral reasons, they might be more likely to be used than classical biowarfare agents. These possibilities have generated new military desires around the world, including within those countries that have publicly renounced biological weapons in the past.


This paper deals predominantly with the last two factors, and with the use of real-life examples, we shall discuss the possibilities for such military abuse of biotechnology.
Read more »

Biological Weapons


Biological Weapons

There are a variety of microorganisms that can be used as biological weapons. Agents are commonly chosen because they are highly toxic, easily obtainable and inexpensive to produce, easily transferable from person to person, can be dispersed in aerosol form, or have no known vaccine. Below is a list of a few potential biological organisms that may be used as biological weapons.
Read more »

Monday, February 22, 2010

Animal Biotechnology Myths & Facts

Myth: Only humans can benefit from medical biotechnology.
Fact: According to USDA, there are 105 licensed biotech products for animals. These products include veterinary vaccines, biologics and diagnostic kits. The animal health industry invests more than $400 million a year in research and development. Current sales of biotech-based products for use in animal health generate $2.8 billion (out of a total market for animal health products of $18 billion).

Myth: Biotech and cloned animals are still years away - improving animals through biotechnology, or cloning them is science fiction.
Fact: The first biotech animal to be sold to the public reached the market in January 2004; GloFish are biotech ornamental fish that contain a gene from a sea anemone. Under black light, the GloFish fluoresce in a brilliant red color. The first cloned-to-order pet, a cat, was delivered to its owner in December 2004. Both biotech GloFish and cloned cats are currently available for purchase by the public. Additionally, there are currently several hundred cloned dairy and beef cattle, though their food products have not been sold to the public. Sheep, cattle, goats, pigs, mice, rabbits, horses, rats, cats and mules have all been successfully cloned in laboratory settings.

Myth: Pets do not benefit from biotechnology at all.
Fact: Companion animals, better known as pets, benefit greatly from vaccines and diagnostic tests based on biotechnology. Biotech-based products to treat heartworm, arthritis, parasites, allergies and heart disease, as well as vaccines for rabies and feline HIV are used daily by veterinarians. Gene therapy has been used to help restore sight to blind dogs, as well as for melanoma, canine lymphoma and bone cancer. Also, some biotechnology companies offer DNA sequencing of purebred animals, such as dogs, for identification purposes.

Myth: Biotech and cloned animals are different from normal animals.
Fact: Studies and experience have shown that biotech animals are animals that eat, drink and behave in ways we are familiar with in their conventional counterparts.

Myth: Animals cannot benefit from biotechnology.
Fact: Biotechnology provides new tools for improving animal health and increasing livestock and poultry productivity. These improvements come from the enhanced ability to detect, treat and prevent diseases and other problems. Additionally, feed from biotech crops are better designed to meet the dietary needs of different farm animals, improve feed efficiency and reduce waste. Just like other assisted reproduction techniques such as artificial insemination, embryo transfer and in vitro fertilization, cloning can also significantly improve animal breeding programs and decrease the occurrence of hereditary diseases and improve the health of animals.

Myth: Wild animals cannot benefit from cloning technology.
Fact: Worldwide, researchers have used cloning technologies to conserve endangered species. In the last four years, scientists have successfully cloned at least three endangered animals: the European mouflon, the guar, and the banteng, the latter of which is viewable to the public at the San Diego Zoo. Several zoos and animal conservation organizations, including the San Diego Zoo, the Zoological Society of London and the Cincinnati Zoo have created "Frozen Zoos" or genetic databases to cryogenically stores samples of DNA, gametes and cell tissues from endangered or threatened mammals, birds and reptiles.

Myth: Biotech will cause disease outbreaks such as avian flu, mad cow disease and West Nile virus in animals and insects, which will be transferred to humans.
Fact: Diseases such as avian flu, mad cow disease and West Nile virus are not related to, nor caused by biotechnology. In fact, researchers are working to find ways to apply biotechnology to eliminate some of these diseases. Scientists in Korea have created biotech cows that may be resistant to mad cow disease, and some research has been done to develop biotech mosquitoes that will no longer infect humans with malaria and other blood-borne diseases.

Myth: Organ transplants from animals are an unreal fantasy.
Fact: Xenotransplantation, or organ transplants from one species to another, is not a new concept, and could be perfected in our lifetime. The idea of xenotransplantation goes back several decades; in fact, in 1984, a U.S. pediatric patient received a baboon heart which worked for 20 days. Today, doctors regularly use valves from pigs' hearts for human heart valve transplants and pigs' skins for skin grafts for human burn victims. Although organ transplants are much more complicated, extensive research has been done on the potential for using biotech animals as blood or organ donors for humans. Biotechnology has been used to address rejection of donor tissues and organs, and biotech pigs have been developed with organs that might resist rapid rejection by the human immune system.

Myth: We are just exploiting animals by applying biotechnology to them.
Fact: The health and well-being of all animals can benefit from biotechnology. The health of companion animals can be significantly improved through the use of biotech vaccines, such as the rabies vaccine, and new diagnostic tests that can identify things such as feline HIV. Domesticated farm animals can greatly benefit from biotechnology through vaccines and diagnostic tests. Improved breeding programs enhanced by biotechnology can drastically improve herd health by eliminating hereditary diseases. Reproduction and breeding techniques influenced by biotechnology, such as in vitro fertilization, artificial insemination can even save endangered species by restoring shrinking populations.
Read more »

Plant Biotechnology Myths & Facts



Plant Biotechnology Myths & Facts

Myth: There are no biotech food products currently on the market.
Fact: Today, it is estimated that at least 70 percent of processed foods on grocery store shelves contain ingredients and oils from biotech crops. The first biotech crop, a tomato improved through biotechnology, was sold in 1994. The first biotech commodity crops - an insect resistant variety of corn - were grown and sold in 1996. Today, the most popular biotech crops are corn, soybean, cotton and canola.

Myth: Biotech foods are unsafe to eat.
Fact: Fact: The Food and Drug Administration (FDA) has determined that biotech foods and crops are as safe as their non-biotech counterparts. The American Medical Association, the American Dietetic Association, and the U.S. National Academy of Sciences have also declared biotech foods safe for human and animal consumption. In addition, since being introduced to U.S. markets in 1996, not a single person or animal has become sick from eating biotech foods. Other international groups that have concluded biotech foods and crops are safe are The United Nations Food and Agriculture Organization, the World Health Organization, the International Council for Science, the French Food Agency, and the British Medical Association. The European Food Safety Authority (EFSA) has also found several biotech varieties to be safe for human and animal consumption.

Myth: Biotech foods are not regulated or tested.
Fact: Biotech crops undergo intense regulatory scrutiny covering their growth in the fields to their delivery in the marketplace to ensure that they are safe for consumption and do not pose any environmental hazards. Biotech crops and their food products are regulated by the U.S. Department of Agriculture (USDA) and the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA). Testing of biotech crops before they are introduced to market generally takes about 6-12 years at a cost of $6-12 million.

Myth: Meat, milk and eggs from livestock and poultry fed biotech feed products are not as safe as similar products from livestock and poultry fed conventionally produced feed.
Fact: Animal feed is often made from biotech crops, and the livestock and poultry that eat these feeds are nourished and healthy from eating biotech foods. The meat, milk and egg products from these farm animals are exactly the same as those from animals eating conventional feed products.In fact, livestock and poultry can actually benefit from feeds made from biotech crops. Some biotech feeds are nutritionally enhanced with added nutrients that improve animal size, productivity and growth. Other biotech feeds can increase digestibility. Biotech feeds also have a positive impact on the environment. Livestock producers are challenged with identifying how to dispose of more than 160 million metric tons of manure annually. Animal manure, especially that of swine and poultry, is high in nitrogen and phosphorus, which can contribute to surface and groundwater pollution. Several biotech feeds decrease phosphorus and nitrogen excretion, total manure excretion and offensive odors.

Myth: Organic or conventional crops are more nutritious or safer than biotech crops.
Fact: Organic and conventionally grown foods are nutritionally comparable to biotech crops. In the future, biotech crops may be even more nutritious. Scientists are working to develop biotech crops that may actually be more nutritious and healthy than conventional and organic crops. For instance, rice has been developed with higher levels of Vitamin A, and future biotech soybeans may produce lower levels of saturated fats and trans fats in oils. Researchers are working to develop allergy-free peanuts and soybeans which will benefit up to seven million Americans who suffer from food allergies.
Myth: Biotech foods taste different than foods made from conventional crops.
Fact: Biotech foods taste exactly the same as regular foods and organic foods. Studies have shown that they do not taste any different, appear any different, nor affect the human body differently. They are also nutritionally equivalent to organic and conventionally grown crops.

Myth: The United States does not require labeling of biotech foods.
Fact: The Food and Drug Administration (FDA) has a labeling policy that requires biotech foods to be labeled if the product is significantly changed nutritionally or uses material from a potential allergen. In other words, if a biotech product is nutritionally the same as a non-biotech product, there is no requirement for labels. However, if a biotech product uses a gene from a peanut, which is a known potential allergen, then it must be labeled. Today, the majority of biotech products in the marketplace are not labeled as such since they are nutritionally equivalent and are not derived from known allergens.
Read more »

VIT-D REDUCES HEART DISEASE AND DIABETES

High Levels of Vitamin D in Older People Can Reduce Heart Disease and Diabetes
Middle aged and elderly people with high levels of vitamin D could reduce their chances of developing heart disease or diabetes by 43%, according to researchers at the University of Warwick.

Read more »

TO PREVENT BREAST CANCER

Few Women Take Tamoxifen to Prevent Breast Cancer
Researchers with the National Cancer Institute (NCI) have found that the prevalence of tamoxifen use for the prevention of breast cancer among women without a personal history of breast cancer is very low.
Read more »

Friday, February 19, 2010

Viruses Helped Shape Human Genetic Variability


Viruses Helped Shape Human Genetic Variability
ScienceDaily (Feb. 19, 2010) — Viruses have played a role in shaping human genetic variability, according to a study published February 19 in the open-access journal PLoS Genetics. The researchers, from the Don C. Gnocchi and Eugenio Medea Scientific Institutes, the University of Milan and the Politecnico di Milano, Italy, used population genetics approaches to identify gene variants that augment susceptibility to viral infections or protect from such infections.
Read more »

Stem cell experiment reverses aging in rare disease


WASHINGTON, Feb. 17, 2010 (Reuters) — In a surprise result that can help in the understanding of both aging and cancer, researchers working with an engineered type of stem cell said they reversed the aging process in a rare genetic disease.
The team at Children's Hospital Boston and the Harvard Stem Cell Institute were working with a new type of cell called induced pluripotent stem cells or iPS cells, which closely resemble embryonic stem cells but are made from ordinary skin cells.
In this case, they wanted to study a rare, inherited premature aging disorder called dyskeratosis congenita. The blood marrow disorder resembles the better-known aging disease progeria and causes premature graying, warped fingernails and other symptoms as well as a high risk of cancer.
It is very rare and normally diagnosed between the ages of 10 and 30. About half of patients have bone marrow failure, which means their bone marrow stops making blood and immune cells properly.
One of the benefits of stem cells and iPS cells is that researchers can make them from a person with a disease and study that disease in the lab. Harvard's Dr. George Daley and colleagues were making iPS cells from dyskeratosis congenita patients to do this.
But, reporting in Thursday's issue of the journal Nature, they said the process of making the iPS cells appeared to reverse one of the key symptoms of the disease in the cells.
In this disease, the cells lose telomerase, an enzyme that helps maintain the telomeres. These are the little caps on the ends of the chromosomes that carry the DNA.
When telomeres unwind, a cell ages. This leads to disease and death
Read more »

Sunday, February 14, 2010

LATEST IN THE WORLD OF BIOTECHNOLOGY

Chicken egg whites - answer to three-dimensional cell culture systems
More and more laboratories are seeking to develop three-dimensional cell culture systems that allow them to test their new techniques and drugs in a system that more closely mimics the way in which cells grow.

DNA Amplification and Detection Made Simple
Twenty-three years ago, a man musing about work while driving down a California highway revolutionized molecular biology when he envisioned a technique to make large numbers of copies of a piece of DNA rapidly and accurately. Known as the polymerase chain reaction, or PCR, Kary Mullis's technique involves separating the double strands of a DNA fragment into single-strand templates by heating it, attaching primers that initiate the copying process, using DNA polymerase to make a copy of each strand from free nucleotides floating around in the reaction mixture, detaching the primers, then repeating the cycle using the new and old strands as templates. Since its discovery in 1983, PCR has made possible a number of procedures we now take for granted, such as DNA fingerprinting of crime scenes, paternity testing, and DNA-based diagnosis of hereditary and infectious diseases.

Read more »